4//SEC Filing
Helash Kevin 4
Accession 0001209191-22-042211
CIK 0001441693other
Filed
Jul 13, 8:00 PM ET
Accepted
Jul 14, 9:33 PM ET
Size
11.0 KB
Accession
0001209191-22-042211
Insider Transaction Report
Form 4
Helash Kevin
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Common Stock
2022-07-12−241,568→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2022-07-12−2,450,000→ 0 totalExercise: $1.16Exp: 2030-08-04→ Common Stock (2,450,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-07-12−417,273→ 0 totalExercise: $0.63Exp: 2032-02-07→ Common Stock (417,273 underlying)
Footnotes (3)
- [F1]Certain unvested restricted stock units became vested and all vested restricted stock units were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement") in exchange for 14,482 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger, and 6,776 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX).
- [F2]This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 237,611 shares and replaced with an option to purchase 15,810 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 9,042 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
- [F3]This option, which provided (1) with respect to 225,000 options, for vesting of 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 3, 2020, with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months; (2) with respect to 2,000,000 options, for vesting if/when performance milestone is attained; and (3) with respect to 225,000 options, for vesting over a period of four years as measured from the vesting commencement date of August 4, 2020, on a pro-rata basis equally each month, was assumed by BIOX in the Merger and replaced with an option to purchase 215,600 Ordinary Shares of BIOX for $13.18 per share.
Documents
Issuer
MARRONE BIO INNOVATIONS INC
CIK 0001441693
Entity typeother
Related Parties
1- filerCIK 0001818849
Filing Metadata
- Form type
- 4
- Filed
- Jul 13, 8:00 PM ET
- Accepted
- Jul 14, 9:33 PM ET
- Size
- 11.0 KB